Makena and Injection site scab - a phase IV clinical study of FDA data

Summary:

Injection site scab is reported as a side effect among people who take Makena (hydroxyprogesterone caproate), especially for people who are female, 30-39 old, and have Premature delivery.

The phase IV clinical study analyzes which people have Injection site scab when taking Makena. It is created by eHealthMe based on reports of 24,287 people who have side effects when taking Makena from the FDA, and is updated regularly.

What is Makena?

Makena has active ingredients of hydroxyprogesterone caproate. eHealthMe is studying from 24,292 Makena users. Check the latest studies of Makena.

What is Injection site scab?

Injection site scab is found to be associated with 88 drugs and 200 conditions by eHealthMe. Check the latest studies of Injection site scab.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 25, 2026

24,287 people reported to have side effects when taking Makena.
Among them, 15 people (0.06%) have Injection site scab.

Among these 15 people:

What is the gender of people who have Injection site scab when taking Makena? *

female: 100 %
male: 0.0 %

What is the age of people who have Injection site scab when taking Makena? *

What are other side effects people have besides Injection site scab? *

Injection Site Pruritus (severe itching at injection site): 9 people, 60.00%
Injection Site Pain: 5 people, 33.33%
Injection Site Mass: 4 people, 26.67%
Injection Site Nodule (small swelling or aggregation of cells in the body, esp. an abnormal one at injection site): 2 people, 13.33%
Hypoaesthesia (reduced sense of touch or sensation): 1 person, 6.67%
Injection Site Bruising: 1 person, 6.67%
Injection Site Discoloration: 1 person, 6.67%
Injection Site Erosion: 1 person, 6.67%
Injection Site Erythema (redness at injection site): 1 person, 6.67%
Injection Site Induration: 1 person, 6.67%

What are the existing conditions these people have? *

Premature Delivery: 10 people, 66.67%
Premature Labor: 1 person, 6.67%
Pain: 1 person, 6.67%
Birth Control: 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Makena and have Injection site scab?

- Check whether Injection site scab is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Makena:

Makena (24,292 reports)

Browse all side effects of Makena:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Injection site scab:

Injection site scab (88 drugs)

Browse all the conditions that are associated with Injection site scab:

Injection site scab (200 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on hydroxyprogesterone caproate (the active ingredients of Makena) and Makena (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.